Zevra Therapeutics, Inc. (ZVRA)
(Delayed Data from NSDQ)
$4.89 USD
+0.07 (1.45%)
Updated May 13, 2024 04:00 PM ET
After-Market: $4.90 +0.01 (0.20%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Income Statements
Fiscal Year end for Zevra Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 27 | 10 | 29 | 13 | 13 |
Cost Of Goods | 3 | 0 | 2 | 1 | 3 |
Gross Profit | 25 | 10 | 27 | 12 | 10 |
Selling & Adminstrative & Depr. & Amort Expenses | 74 | 53 | 19 | 18 | 30 |
Income After Depreciation & Amortization | -50 | -43 | 8 | -6 | -20 |
Non-Operating Income | 5 | 1 | -16 | 0 | 2 |
Interest Expense | 2 | 0 | 0 | 7 | 7 |
Pretax Income | -46 | -42 | -9 | -13 | -25 |
Income Taxes | 0 | -1 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -46 | -42 | -9 | -13 | -25 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -46 | -42 | -9 | -13 | -25 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -49 | -42 | 8 | -3 | -18 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 0 | 3 | 2 |
Income After Depreciation & Amortization | -50 | -43 | 8 | -6 | -20 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 35.45 | 34.49 | 29.77 | 3.98 | 1.85 |
Diluted EPS Before Non-Recurring Items | -1.30 | -0.69 | -1.23 | -3.00 | -14.08 |
Diluted Net EPS (GAAP) | -1.30 | -1.20 | -2.11 | -3.21 | -13.28 |
Fiscal Year end for Zevra Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 3.43 | 13.22 | 2.90 | 8.47 | 2.88 |
Cost Of Goods | 0.18 | 2.00 | 0.14 | 0.68 | 0.13 |
Gross Profit | 3.25 | 11.22 | 2.75 | 7.79 | 2.75 |
SG&A, R&D, and Dept/Amort Expenses | 23.74 | 25.89 | 18.12 | 14.44 | 15.67 |
Income After SG&A, R&D, and Dept/Amort Expenses | -20.49 | -14.67 | -15.37 | -6.65 | -12.92 |
Non-Operating Income | 4.53 | 0.27 | 1.86 | 1.68 | 1.24 |
Interest Expense | 0.74 | 0.76 | 0.37 | 0.20 | 0.18 |
Pretax Income | -16.69 | -15.15 | -13.87 | -5.16 | -11.87 |
Income Taxes | -0.07 | 0.00 | 0.18 | -0.07 | -0.10 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -16.62 | -15.15 | -14.05 | -5.08 | -11.77 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -16.62 | -15.15 | -14.05 | -5.08 | -11.77 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 41.78 | 37.88 | 34.73 | 33.90 | 34.47 |
Diluted EPS Before Non-Recurring Items | -0.40 | -0.40 | -0.40 | -0.15 | -0.34 |
Diluted Net EPS (GAAP) | -0.40 | -0.41 | -0.40 | -0.15 | -0.34 |